Kornimate/medical-research-clean huggingface dataset:
exercise rehabilitation in veterans with pad

Conditions: Peripheral Arterial Disease; Intermittent Claudication

Summary: peripheral artery disease (pad) results in blockages of arteries (blood vessels) and decreased blood flow to the legs. this may cause difficulty or pain with walking or other activities that use leg muscles. exercise may help improve blood flow in the legs and improve the ability to walk. this research project will be conducted patients with pad that require revascularization. the goal is to examine the effects of 3 months of exercise rehabilitation or neuromuscular stimulation on leg blood flow, physical function, quality of life and general health.

peripheral artery disease (pad) and its associated declines in physical function impair quality of life (qol) in nearly 20% of older veterans and result in substantial va health care costs. revascularization addresses the anatomical pathology, but does not restore mobility function and qol. optimal therapy may require post-revascularization rehabilitation to address lingering defects in skeletal muscle that limit function; however, the current standard of care after revascularization does not include rehabilitation. exercise training and neuromuscular electrical stimulation (nmes) may enhance function by increasing muscle perfusion to improve outcomes in older veterans with pad after revascularization. the investigators will enroll veterans (50-80 years of age) with pad who are planned for percutaneous revascularization. participants will complete research testing consisting of: a) assessment of mobility function and qol; and b) treadmill tests to assess ambulatory capacity, and calf muscle perfusion. participants will undergo screening prior to revascularization and will have baseline testing 2-3 weeks after revascularization. after post-revascularization testing, patients will be randomized to exercise-only or nmes-only. after completion of the 3-month intervention, participants will repeat all tests to determine the effects of the interventions.

Eligibility criteria:
inclusion criteria: * diagnosis of peripheral arterial disease; or ankle-brachial index \<0.9. * planned to undergo endovascular revascularization within 6 months. exclusion criteria: * cancer under active treatment * planned for lower extremity bypass surgery * body mass index \> 45 kg/m2 * critical limb ischemia or lower extremity gangrene

Keywords: rehabilitation exercise training
effectiveness and safety of platelet rich plasma (prp) on persistent olfactory dysfunction related to covid-19

Conditions: Anosmia; COVID-19

Summary: olfactory dysfunction (od) is a well know symptom of coronavirus disease 2019 (covid-19), accounting for 48 to 85% of patients. in 1 to 10% of cases, patients develop a chronic olfactory dysfunction (cod,) lasting more than 6 months. recently, platelet-rich plasma (prp) was used in patients with non-covid-19 cod and authors reported encouraging results. in the present study, the investigators investigated the usefulness and safety of prp injection in 56 patients with covid-19 cod. our results showed that prp in the olfactory cleft can increase the olfactory threshold one month after the injection. moreover, our results suggest that timing of treatment may be an important factor and that prp is a safe treatment because no adverse effects were reported throughout the study


Eligibility criteria:
inclusion criteria: * patient chronic olfactory dysfunction lasting more than 6 months after an infection of covid-19 exclusion criteria: * patient under 18 years old * patient with blood disorder * blood thinner user * patient with abnormal findings on nasal endoscopy (e.g., polyposis, rhinosinusitis)

Keywords: prp anosmia covid-19
perenteral nutrition and oxidative stress in preterm infants

Conditions: Preterm Infants

Summary: in an effort to decrease the load of peroxides in tpn solutions, multiple studies examined different strategies such as photo-protection, adding multivitamins to the lipid emulsion rather than to the dextrose-amino acid admixture, and adding antioxidants such as glutathione to the tpn solution. however, the role of trace elements as antioxidants, and their interaction with light have not been studied. also, the impact of tpn-related oxidants on clinical morbidities has not been addressed. therefore, we aimed in this study of preterm infants to evaluate the role of different components of tpn on urinary peroxides and to examine the biochemical and clinical effects of light protection.


Eligibility criteria:
inclusion criteria: preterm infants included are: 1. with gestational age between 28 to 34 weeks 2. managed with tpn as part of their care in the nicu 3. their postnatal age on enrolment was \< 7 days exclusion criteria: infants are excluded if they have: 1. clinical evidence of sepsis, or a positive blood culture on admission 2. hepatobiliary dysfunction 3. persistent metabolic acidosis with base deficit \> 10 meq / l 4. renal impairment (urine output \ 1 mg/dl) 5. disseminated intravascular coagulopathy 6. maternal conditions known to be associated with oxidative stress such as preeclampsia, hypertension and diabetes.

Keywords: preterm parenteral nutrition tpn lipid emulsions photo-protection oxidative stress
treatment of caesarean scar pregnancy

Conditions: Caesarean Scar Pregnancy

Summary: the aim of this study is to further demonstrate the safety and effectiveness of transvaginal resection of pregnancy tissue in the treatment of caesarean scar pregnancy (csp).


Eligibility criteria:
inclusion criteria: * pre-operative diagnosed as csp * hemodynamic stability exclusion criteria: * cervical pregnancy * incomplete abortion * gestational trophoblastic disease * diagnosis unidentified

Keywords: caesarean scar pregnancy transvaginal resection treatment
recognizing ventricular fibrillation from an area of a mobile phone

Conditions: Ventricular Fibrillation

Summary: recognition of out of hospital cardiac arrest (ohca) during an emergency call is based on standardized questions concerning the symptoms of ohca. with this method cardiac arrest is recognized in 50-83% of cases. when the emergency medical dispatcher identifies cardiac arrest during the emergency call the survival of the patient improves. accurate emergency medical service response is activated promptly and bystander will receive cardiopulmonary resuscitation (cpr) instructions. it has been estimated that proper implementation of cpr instructions will save thousands of lives each year. if the ecg could be recorded by the mobile phone, transmitted during the emergency call to the dispatch centre and analysed there with the software of a semi-automated external defibrillator(aed), the recognition of cardiac arrest could be more accurate. the aim of this study is to examine, if aed, with minimal size electrodes within an area of a mobile phone, is able to recognize reliably ventricular fibrillation (vf), the rhythm with the best prognosis in ohca.

dysrhythmia patients who need an implantable cardioverter defibrillator(icd) or patients with an already implanted icd which function needs to be revised will be recruited into this study. our hypothesis is that the ecg and vf is recordable in 100% of cases with a semi-automatic defibrillator. in sample size calculations we compared this 100% recognition to the present situation with 80% recognition of cardiac arrest in emergency medical communication centre during emergency call. according to the power calculation of 1-sided binomial test with risk level 0.05 and power of 95 %, 22 observations is needed to detect difference between expected full successes (99 %) from the previous 80 % of successes in recognition.

Eligibility criteria:
inclusion criteria: * age over 18 * ventricular fibrillation will be induced during the implantation or revision of icd * patient's informed consent exclusion criteria: * ventricular fibrillation will not be induced during the implantation or revision of icd

Keywords: ventricular fibrillation cardiac arrest mobile technology
a study of 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: this study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.


Eligibility criteria:
inclusion criteria: * diagnosis of open-angle glaucoma or ocular hypertension * no use of lumigan® in the past 3 months exclusion criteria: * received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months
role of hyaluronic acid in causing cancer stem cell growth in the bones of patients with breast cancer

Conditions: Breast Carcinoma Metastatic to the Bone; Stage IV Breast Cancer

Summary: this research trial studies the role of a substance called hyaluronic acid in causing the growth of cancer stem cells in the bones of patients with breast cancer. cancer stem cells are a type of cancer cells that may cause the cancer to spread to other parts of the body. studying samples of blood and bone marrow from patients and animal models in the laboratory may help doctors learn more about whether hyaluronic acid affects the growth of cancer in the bones.

primary objectives: i. to evaluate the hypothesis that there are more hyaluronan synthase 2 (has2)+ cells in patients with bone metastasis compared to patients with only local disease. secondary objectives: i. to evaluate the hypothesis that cells with has2+ and cancer stem cell (csc)+ (cluster of differentiation \[cd\]24-/cd44+/epithelial specific antigen \[esa\]+) cells will have the most aggressive growth in the bone, using an animal model. outline: blood and bone marrow samples are collected and analyzed via flow cytometry and polymerase chain reaction (pcr). cells are also transplanted into mice and studied.

Eligibility criteria:
inclusion criteria: * patients must have newly diagnosed, histologically confirmed primary and/or metastatic breast cancer * ability to understand and the willingness to sign an institutional review board (irb)-approved informed consent document exclusion criteria: * patients who have had chemotherapy or radiotherapy
study and monitoring of multiple endocrine neoplasia type 1

Conditions: MEN1

Summary: multiple endocrine neoplasia type i (men1) is a rare autosomal dominant disorder, predisposing sufferers to the development of endocrine tumors. the three most commont endocrine disorders of men1 are the secretory tumours of the parathyroid, pituitary gland and pancreas, in addition to which other tumours may be observed. the diagnosis of men1 is essential for 1) appropriate therapeutic management of proven endocrine disorders, 2) screening for other endocrine and non-endocrine tumours, 3) family screening of affected relatives and 4) monitoring of patients who have been diagnosed. undiagnosed men1 is one of the reasons for therapeutic failure in the management of endocrine damage. detection is therefore of major importance, and any improvement in early diagnosis can improve management. the natural history of the disease in all its clinical forms remains poorly understood, with published studies of selected or small populations. there are still clinical forms that are difficult to link to the syndrome. these clinical forms need to be specified in order to ensure optimal management. only a large cohort will lead to the identification of the various forms of this condition and clarify its prognosis.


Eligibility criteria:
inclusion criteria: symptomatic patients * person (adult or minor) who has not opposed participation * if the patient is a minor, the parents must not oppose their child's participation, * at least two of the three main types of lesions (parathyroid, pancreas, pituitary gland) * or a known isolated tumor, main type or not, associated with the gene mutation of the nem1 locus on chromosome 11q13 * or an isolated tumor, main type or not, in an individual with a confirmed family history of nem1 asymptomatic patients with a mutation - presence of a characteristic mutation of nem1 exclusion criteria: na
35 kda hyaluronan fragment (ha35) reduces chronic inflammation of skin

Conditions: Skin Inflammation; Cosmetic Skin

Summary: to explore the clinical effect and safety of 35 kda hyaluronic acid fragment ( ha35 ) combined with negative pressure microneedle technology in improving skin problems.


Eligibility criteria:
inclusion criteria: * skin problems include but are not limited to dry skin, dark skin, and coarse pores. * chronic skin inflammation, pigmentation, erythema, etc. * cooperate with the experimental requirements and be able to complete the score independently。 exclusion criteria: * pregnant or lactating women. * suffering from psychological or mental illness. * life is not regular, overeating. * hypersensitive to hyaluronic acid, and has a scar constitution.

Keywords: whitening pore size skin dryness erythema skin hardness
sponge application of mmc versus suntenon injection in trabeculectomy

Conditions: Trabeculectomy; Glaucoma

Summary: glaucoma is a leading cause of irreversible blindness worldwide, with intraocular pressure (iop) reduction being the primary therapeutic goal. trabeculectomy, augmented with mitomycin c (mmc), remains the gold standard surgical intervention but is limited by postoperative fibrosis. mmc delivery methods, including sponge application and sub-tenon injection, vary in drug distribution and may influence surgical outcomes. this study aimed to compare the efficacy and safety of trabeculectomy using sponge-applied mmc versus sub-tenon mmc injection, focusing on iop reduction, bleb morphology, and postoperative medication requirements. in this retrospective, randomized controlled trial, 50 patients with primary or secondary glaucoma were assigned to trabeculectomy with either mmc sponge application (group a, n=25) or sub-tenon mmc injection (group b, n=25). all surgeries were performed by the same surgeon using standardized techniques. patients were followed for one year, with primary outcomes including iop reduction and secondary outcomes encompassing bleb morphology (indiana bleb appearance grading scale), bleb integrity (seidel test), and postoperative glaucoma medication use.


Eligibility criteria:
inclusion criteria: * 18 years or older, * diagnosed with primary open-angle glaucoma (poag) or secondary glaucoma, * uncontrolled iop (iop \> 21 mmhg) despite maximally tolerated medical therapy, * progressive visual field deterioration, * or intolerance to anti-glaucoma medications. exclusion criteria: * age under 18 years, * absence of light perception, * previous incisional glaucoma surgery, * need for combined ocular procedures, * intraoperative use of 5-fluorouracil (5-fu), * or follow-up duration of less than one month
comparative study of influenza vaccines in adults, fluvacs-year 4

Conditions: Influenza

Summary: the purpose of this study is to evaluate the absolute (versus placebo) and relative (one vaccine compared to the other) efficacies of the live attenuated and inactivated influenza vaccines in preventing laboratory confirmed symptomatic influenza caused by circulating strains whether similar or dissimilar to strains included in the vaccines.


Eligibility criteria:
inclusion criteria: * healthy adult men and women * age 18-49 years * who reside geographically close to one of the four study sites in michigan exclusion criteria: * persons with any of the health conditions for which the inactivated vaccine is recommended * persons for whom either vaccine is contraindicated

Keywords: influenza live attenuated influenza vaccine inactivated influenza vaccine vaccine efficacy
a randomized, double-blind, placebo controlled trial evaluating the impact of nystatin on the development of oral irritation in patients receiving high dose intravenous interleukin-2

Conditions: Candidiasis, Oral; Gastrointestinal Diseases; Stomatitis

Summary: in patients who are receiving intravenous high dose interleukin-2, patients will be randomized into two groups: group one will receive nystatin swish and swallow immediately before initiation of il-2, and the second group will receive a placebo. the patients in each group will be monitored and evaluated for differences in the rate and severity of development of oral irritation during treatment. they will also be studied for differences between the two groups in the number of doses of il-2 taken.

in patients who are receiving intravenous high dose interleukin-2, patients will be randomized into two groups: group one will receive nystatin swish and swallow immediately before initiation of il-2, and the second group will receive a placebo. the patients in each group will be monitored and evaluated for differences in the rate and severity of development of oral irritation during treatment. they will also be studied for differences between the two groups in the number of doses of il-2 taken.

Eligibility criteria:
all patients enrolled on high dose intravenous interleukin-2 studies in the surgery branch of the national cancer institute are eligible, except for patients who are receiving adoptively transferred cells (cloned peripheral blood cells). all inclusion criteria as stated in the parent immunotherapy protocol apply: no patients with evidence of oral irritation prior to starting therapy; no patients with any known sensitivity to nystatin; no patients receiving systemic antifungals; no patients with active oral infections. in additional, all exclusion criteria as stated in the parent immunotherapy protocol.

Keywords: mucositis oral candidiasis prophylaxis stomatitis swish and swallow
dermal fillers patient satisfaction

Conditions: Loss of Facial Fat

Summary: the face is arguably the most critical aesthetic unit of the body. as humans begin to age, numerous changes occur to the face. changes include the formation of wrinkles, soft-tissue atrophy, gravitational descent resulting in sagging skin, loss of skin and muscle tone, and changes in bony architecture. these changes are potentiated in our population secondary to sun exposure and smoking. to combat the effects of aging on the face, a multitude of products and procedures exist to attempt to reverse the effects of sun damage and aging to achieve a youthful and rejuvenated appearance. there has been a shift from invasive procedures such as a facelift to noninvasive means using filling agents to restore lost contour deformities. the investigators hypothesis is that the use of dermal filling agents effectively delays the need for invasive procedures such as facelifts, and that patient satisfaction has increased with the evolution of recent dermal filling agents.

the first part of this study will involve a retrospective review of patients who have had a dermal filler injection between 01/01/1998 through 12/31/2008 and then following up with one (1) patient satisfaction survey. the first part of the study, which is retrospective, may involve approximately 500 subjects. the data collected from the retrospective review will be the subject's name, medical record number, and address for contact information. any other data collected will come from the answers on the questionnaire. the second part of this study will be a prospective study involving 100 subjects who are scheduled to have a dermal filler injection. these subjects will be asked to complete one (1) patient satisfaction survey two weeks after injection. facial photos will be taken before the injection and then two weeks after injection at the follow up visit. this will complete the subject's participation in this study.

Eligibility criteria:
inclusion criteria: * subjects from 21 - 80 years of age who are scheduled to have a dermal filler injection. exclusion criteria: * subjects under 21 years of age or older than 80 years of age will be excluded from this study.

Keywords: facialwasting juvederm restylane
a phase i, open-label, multicentre study to evaluate the safety, tolerability and pharmacokinetics of medi4736 in patients with advanced solid tumours

Conditions: Advanced Solid Tumors

Summary: this is a phase i, open-label, multicentre study of medi4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor followed by an expansion phase in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: * in the dose-escalation phase: patients with advanced solid tumors refractory to standard treatment, intolerant of standard treatment, or for which no standard therapy exists. in the dose-expansion phase: histologically- or cytologically-confirmed advanced or metastatic biliary tract cancer (btc), esophagus cancer(ec) (squamous cell carcinoma) or squamous cell carcinoma of the head and neck (scchn). - men or women. - eastern cooperative oncology group (ecog) status of 0 or 1. - adequate organ and marrow function. - subjects must have at least 1 measurable lesion. - available archived tumor tissue sample. - willingness to provide consent for biopsy samples. exclusion criteria: * any prior grade ≥ 3 irae while receiving immunotherapy - prior exposure to any anti-pd-1 or anti-pd-l1 antibody - active or prior documented autoimmune disease within the past 2 years - history of primary immunodeficiency - symptomatic or untreated central nervous system (cns) metastases requiring concurrent treatment - women who are pregnant or lactating - uncontrolled intercurrent illness - known history of tuberculosis - known to be human immunodeficiency virus (hiv) positive - hepatitis b or c infection - other invasive malignancy within 5 years

Keywords: medi4736 advanced solid tumors squamous cell carcinoma of the head and neck biliary tract cancer squamous cell carcinoma of esophagus cancer b7-h1 pd-l1
study of ontak (denileukin diftitox) in previously treated cutaneous t-cell lymphoma patients

Conditions: Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Sezary Syndrome

Summary: the purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ontak. it is also designed to determine the effectiveness of ontak in cutaneous t-cell lymphoma (ctcl) patients whose tumors do not express cd25.


Eligibility criteria:
inclusion criteria: * patient must have been previously enrolled in protocol 93-04-11 and randomized to the placebo arm; or the patient met all eligibility criteria for protocol 93-04-11 other than the expression of cd25 on ctcl tumor cells. * ctcl disease stage ia - iii. * history of less than or equal to 3 previous therapies. repeated use of the same agent is considered to be 1 therapy unless it is part of a different combination regimen. only 1 prior combination cytotoxic chemotherapy regimen is permitted. topical or systemic steroids are not considered a therapy. * patient must have evaluable or measurable disease. lymph node involvement no greater than ln2. no ctcl involvement of bone marrow. * no significant pulmonary or cardiac disease. no active cns, kidney, or liver disease. * no systemic infections. * ecog performance status of 0 or 1. exclusion criteria: • the 93-04-14 study is no longer open to subjects previously enrolled in 93-04-10 or 92-04-01.